Cancer Immunotherapy

James Allison (Author), Glen Dranoff (Author)

9780120224890, Elsevier Science

Hardback, published 19 May 2006

400 pages, Illustrated
22.9 x 15.1 x 2.6 cm, 0.77 kg

PRAISE FOR THE SERIES:
"...among the most active volumes in the libraries of our universities and institutions." --SCIENCE

"A provocative and scholarly review of research." --JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

For some time immunotherapy has been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, the approach needs considerable refinement. Whilst some programmes are looking to increase the understanding of molecular and cellular mechanisms underlying the stimulation of antitumor immunity, others are trying to find the most appropriate clinical setting that will reveal the role of the immune system in combating cancer. Among the most important discoveries have been tumor-specific antigens.

This thematic volume highlights some key issues and discusses where they may move forward. It has been put together by two leading cancer immunotherapists from two eminent institutions that focus on cancer research.

Engineered cellular vaccines
Blockade of T cell checkpoints.
Serex in the identification of target antigens
New approaches to tumor immunotherapy
Melanoma antigens
Antibodies and chimeric molecules
Tumor Immunosurveillance
Dendritic Cells
Strategies for Tumor Vaccination
DNA vaccines

Subject Areas: Biophysics [PHVN], Immunology [MJCM], Oncology [MJCL], Public health & preventive medicine [MBN]